{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:19:12Z","timestamp":1779113952040,"version":"3.51.4"},"reference-count":39,"publisher":"SAGE Publications","issue":"2_suppl","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:p>Hyperprolactinaemia may be associated with hidden longer-term consequences, such as osteoporosis, bone fractures, pituitary tumours and breast cancer. Prolactin data from clinical trials is not always reported in a categorical manner and does not always allow the risk of hyperprolactinaemia to be evaluated for specific patient cohorts. Patients participating in a physical health management programme in the UK for severe mental illness patients \u2014 the Well-being Support Programme \u2014 had prolactin measurements made regardless of symptoms. Prolactin data from the complete cohort of 178 patients receiving antipsychotics in Leeds and London are reported. Hyperprolactinaemia was measured in 33.1% but more commonly in females than males (47.3% and 17.6%) and was associated with all antipsychotics except clozapine. The highest prevalence rates were found in amisulpride (n=20) 89%, risperidone long-acting intramuscular injection (LAIM) 67% (n=6) and risperidone (n=30) 55% used as antipsychotic monotherapy. Clinically Significant hyperprolactinaemia (&gt;1000 mIU\/L ~47 ng\/ml) was measured in 15.8% of patients, predominantly in females. Levels &gt;2000 mIU\/L ~95 ng\/ml in 6.2% of the complete cohort. Clinicians may wish to add prolactin measurement to the routine laboratory parameters currently measured for some antipsychotics and should be advised of the potential longer-term consequences of hidden hyperprolactinaemia.<\/jats:p>","DOI":"10.1177\/0269881107088436","type":"journal-article","created":{"date-parts":[[2008,5,13]],"date-time":"2008-05-13T07:38:40Z","timestamp":1210664320000},"page":"56-62","source":"Crossref","is-referenced-by-count":39,"title":["Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics"],"prefix":"10.1177","volume":"22","author":[{"given":"Chris","family":"Bushe","sequence":"first","affiliation":[{"name":"Eli Lilly and Company Ltd, Basingstoke, UK, beesbeesbees@blueyonder.co.uk,\rbushe_chris@lilly.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yeomans","sequence":"additional","affiliation":[{"name":"Leeds Mental Health Teaching NHS Trust, Clarence House,\r11 Clarence Road, Horsforth, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamsin","family":"Floyd","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry at Kings College London, PO\rBox 23, Decrespigny Park, Camberwell, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubulade M","family":"Smith","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry at Kings College London, PO\rBox 23, Decrespigny Park, Camberwell, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,3,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0704"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107078281"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107088435"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107087373"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80086-7"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00112-9"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082624"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.106.023671"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.162"},{"key":"atypb11","volume-title":"Risperidal (risperidone) home page","year":"2005"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n0206"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00127-0"},{"key":"atypb14","first-page":"419","volume":"25","year":"2004","journal-title":"Neuro Endocrinol Lett"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-72-2-256"},{"issue":"2","key":"atypb16","first-page":"1","volume":"161","year":"2004","journal-title":"Am J Psychiatry"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051688"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881103174011"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.184.6.503"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2007.01.013"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v65n1108"},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2850.2005.00884.x"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000150223.31007.e0"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.07.006"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.5.947"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.181.1.49"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00002"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01605.x"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.748"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1870"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.01.032"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3369"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.6356"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.59.12.1147"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7332.250"},{"key":"atypb36","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.182.3.199"},{"key":"atypb37","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2006.11.004"},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1781(02)00022-7"},{"key":"atypb39","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0712"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881107088436","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881107088436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:10:41Z","timestamp":1777507841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881107088436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":39,"journal-issue":{"issue":"2_suppl","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1177\/0269881107088436"],"URL":"https:\/\/doi.org\/10.1177\/0269881107088436","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}